MedTrace Logo

Alcohol and ART Adherence in India

NCT03746457 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 940

Last updated 2018-12-11

No results posted yet for this study

Summary

The focus of this project was to reduce alcohol consumption among male "persons living with HIV" (PLHIV) on antiretroviral treatment (ART) at government hospitals in urban Maharashtra, India and factors associated with both these outcomes including depression, stigma, social support networks, quality of life and health status. The project consisted of three phases; formative research, implementation of multilevel interventions and analysis of process and outcome data. The project utilized a crossover design to compare outcomes of individual interventions and the sequences of intervention.

Conditions

  • Alcohol Consumption
  • HIV Infection Primary

Interventions

BEHAVIORAL

Behavioral intervention

Individual counseling, group intervention, collective advocacy

Sponsors & Collaborators

  • Institute for Community Research

    collaborator UNKNOWN

  • International Center for Research on Women

    collaborator UNKNOWN

  • Population Council

    collaborator OTHER

  • UConn Health

    lead OTHER

Principal Investigators

  • Stephen L Schensul, PhD · UConn Health

  • Jean J Schensul, PhD · Institute for Community Research

  • Niranjan Saggurti, PhD · Population Council, India Country office

  • Avina Sarna, MD · Population Council, India Country office

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-10
Primary Completion
2018-10-15
Completion
2018-10-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03746457 on ClinicalTrials.gov